Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 | P08172 | 3/20 | 0.51 |
| ▸ | CHRM1 | P11229 | 3/20 | 0.51 |
| ▸ | OPRD1 | P41143 | 2/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.37 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | OGA | O60502 | 7/20 | 0.35 |
| ▸ | MOGAT2 | Q3SYC2 | 2/20 | 0.34 |
| ▸ | IDH1 | O75874 | 1/20 | 0.33 |
| ▸ | KCNA5 | P22460 | 1/20 | 0.33 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18291593 | 0.80 | CHRM2 (0.48) | CHRM2CHRM1OPRD1CYP2D6CYP19A1 | |
| SCHEMBL18291412 | 0.79 | CHRM2 (0.47) | CHRM2CHRM1OPRD1CYP2D6CYP19A1 | |
| SCHEMBL24323620 | 0.79 | CHRM2 (0.47) | CHRM2CHRM1CYP2D6CYP19A1MEN1 | |
| SCHEMBL20255517 | 0.79 | CHRM2 (0.47) | CHRM2CHRM1OPRD1CYP2D6CYP19A1 | |
| SCHEMBL20037435 | 0.77 | CHRM2 (0.45) | CHRM2CHRM1OPRD1CYP2D6CYP19A1 | |
| SCHEMBL15318609 | 0.74 | CHRM2 (0.58) | CHRM2CHRM1OPRD1CYP2D6CYP19A1 | |
| SCHEMBL20883792 | 0.72 | CHRM2 (0.59) | CHRM2CHRM1OPRD1CYP2D6CYP19A1 | |
| SCHEMBL12145921 | 0.72 | CHRNB2 (0.58) | — | |
| SCHEMBL1694606 | 0.71 | CHRNA7 (0.38) | CYP2D6IDH1 | |
| SCHEMBL16026426 | 0.71 | KCNA5 (0.53) | CHRM2CHRM1CYP2D6MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180161329-A1 | PYRIDO[3,4-D]PYRIMIDINE DERIVATIVE AND PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | TEIJIN PHARMA LIMITED (JP) | 2018-06-14 | — | — | US | disclosed |
| US-20180161329-A1 | PYRIDO[3,4-D]PYRIMIDINE DERIVATIVE AND PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | TEIJIN PHARMA LIMITED (JP) | 2018-06-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180161329-A1 | PYRIDO[3,4-D]PYRIMIDINE DERIVATIVE AND PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | CDK4, CDK6, CDK16 | CHRM2 4833/4885CHRM1 4851/4885OPRD1 3922/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.